Systemic Lupus Erythematosus
Conditions
Interventions
None listed
Sponsors
Meiji Pharmaceutical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Clinical studies are included if they meet the following criteria: 1) randomized controlled trial; 2) adult patients (18 years or older) diagnosed with SLE; 3) belimumab was the intervention drug (Regardless of route of administration); 4) improvement in SLE symptoms and safety were evaluated.
Exclusion criteria
Exclusion criteria: We exclude clinical studies that meet the following exclusion criteria: 1) not interventional studies; 2) non-original research articles such as reviews, case reports, letters, and research protocols; 3) no data description; 4) studies in children; 5) patients with lupus nephritis; 6) single-dose studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients who achieved a >= 4-point reduction in SLE Disease Activity Index (SLEDAI) score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients whose BILAG score did not worsening, Number of patients whose PGA score did not worsening, Short Form 36 health survey (SF-36) score, and SLICC/ACR damage index (SDI), Number of adverse events. | — |
Countries
Japan
Contacts
Public ContactYosuke Suzuki
Meiji Pharmaceutical University Department of Medication Use Analysis and Clinical Research
Outcome results
None listed